Document Type
Article
Publication Date
1-26-2025
Abstract
Adaptive immune resistance in cancer describes the various mechanisms by which tumors adapt to evade anti-tumor immune responses. IFN-γ induction of programmed death-ligand 1 (PD-L1) was the first defined and validated adaptive immune resistance mechanism. The endoplasmic reticulum (ER) is central to adaptive immune resistance as immune modulatory secreted and integral membrane proteins are dependent on ER. Sigma1 is a unique ligand-regulated integral membrane scaffolding protein enriched in the ER of cancer cells. PD-L1 is an integral membrane glycoprotein that is translated into the ER and processed through the cellular secretory pathway. At the cell surface, PD-L1 is an immune checkpoint molecule that binds PD-1 on activated T-cells and blocks anti-tumor immunity. PD-L1 can also be incorporated into cancer cell-derived extracellular vesicles (EVs), and EV-associated PD-L1 can inactivate T-cells within the tumor microenvironment. Here, we demonstrate that a selective small molecule inhibitor of Sigma1 can block IFN-γ mediated adaptive immune resistance in part by altering the incorporation of PD-L1 into cancer cell-derived EVs. Sigma1 inhibition blocked post-translational maturation of PD-L1 downstream of IFN-γ/STAT1 signaling. Subsequently, EVs released in response to IFN-γ stimulation were significantly less potent suppressors of T-cell activation. These results suggest that by reducing tumor derived immune suppressive EVs, Sigma1 inhibition may promote antitumor immunity. Sigma1 modulation presents a novel approach to regulating the tumor immune microenvironment by altering the content and production of EVs. Altogether, these data support the notion that Sigma1 may play a role in adaptive immune resistance in the tumor microenvironment.
Recommended Citation
Castagnino, Paola A.; Haas, Derick A.; Musante, Luca; Tancler, Nathalia A.; Tran, Bach V.; Kean, Rhonda; Steck, Alexandra R.; Martinez, Luis A.; Mostaghel, Elahe A.; Hooper, D. Craig; and Kim, Felix J., "Sigma1 Inhibitor Suppression of Adaptive Immune Resistance Mechanisms Mediated By Cancer Cell Derived Extracellular Vesicles" (2025). Department of Pharmacology, Physiology, and Cancer Biology Faculty Papers. Paper 33.
https://jdc.jefferson.edu/ppcbfp/33
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Language
English
Comments
This article is the author's final published version in Cancer Biology & Therapy, Volume 26, Issue 1, January 2025, Article number 2455722.
The published version is available at https://doi.org/10.1080/15384047.2025.2455722.
Copyright © 2025 The Author(s).